Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 130 participants.
Also called NCT04952610
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 130 participants
- Registry
-
NCT04952610
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Canada
- Registry status
- Completed
Technical summary
Registry record NCT04952610. Allocation not applicable; no masking; primary purpose treatment. Start 2021-12-13 (actual); primary completion 2026-04-10 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Etripamil Nasal Spray in Patients With Paroxysmal Supraventricular Tachycardia
- Condition
- Paroxysmal Supraventricular Tachycardia
- Intervention (Drug)
- Etripamil NS 70 mg
- Intervention (Device)
- Aptar Pharma Nasal Spray Bidose System
- Lead sponsor
- Milestone Pharmaceuticals Inc.
Record details
- Record id
cardio:ct-nct04952610- Content hash
03c17beb086819d19917e6b7e4a7943df613d52a95b1355f1f58ce3814372402